The effects of anagliptin on plasma lanosterol, sitosterol, campesterol level in patients with type 2 diabetes mellitus

INTERVENTION: Anagliptin 100mg‐200mg x 2/day CONDITION: Type 2 diabetes mellitus PRIMARY OUTCOME: The primary outcome is changes in LDL‐cholesterol at 6 months. SECONDARY OUTCOME: The secondary outcome is changes on plasma lanosterol, sitosterol, campesterol level in patients with type 2 diabetes mellitus INCLUSION CRITERIA: 1) Type 2 diabetic patients, who has inadequate glycemic control, being treated with on diet and exercise or oral hypoglycemic agent 2) HbA1c<8.0% 3) More than 20 years (at the time of informed consent date) 4) Ability to provide written informed consent for this study